Swan Capital’s GSK GSK Stock Holding History

Swan Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.67K	Hold	89	–	–	﹤0.01%	273
2026 Q1	$4.91K	Sell	89 -200	-69%	-$10.8K	﹤0.01%	262
2025 Q4	$14.2K	Hold	289	–	–	0.01%	150
2025 Q3	$12.5K	Sell	289 -110	-28%	-$4.3K	0.01%	147
2025 Q2	$15.3K	Buy	399 +119	+43%	+$4.55K	0.01%	132
2025 Q1	$10.8K	Hold	280	–	–	0.01%	137
2024 Q4	$9.47K	Hold	280	–	–	﹤0.01%	136
2024 Q3	$11.4K	Hold	280	–	–	0.01%	136
2024 Q2	$10.8K	Buy	+280	New	+$11.8K	0.01%	126

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Swan Capital's GSK Position: Q2 2026 in Review

Swan Capital held its GSK (GSK) position steady in Q2 2026 at 89 shares worth $4.67K. The position accounts for ﹤0.01% of the portfolio, ranked #273.

Swan Capital first reported a position in GSK in Q2 2024 and has held it in 9 quarters since. The position peaked at $15.3K in Q2 2025. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Swan Capital held 89 shares of GSK worth $4.67K as of Q2 2026.
Swan Capital left its GSK share count unchanged in Q2 2026.
GSK made up ﹤0.01% of Swan Capital's portfolio in Q2 2026, its #273 holding.
Swan Capital first reported a position in GSK in Q2 2024 and has held it in 9 quarters since.
Swan Capital's GSK position peaked at $15.3K in Q2 2025.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Swan Capital's 13F filing for Q2 2026, filed 13 Aug 2026.